Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

UK Health Body Approves Novartis's Tasigna For CML

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2012 | 01:16am CET

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
02/16 JOHNSON & JOHNSON : Nancy-Ann DeParle and Dr. Scott Gottlieb Join Executives fro..
02/15 NOVARTIS : Sources Sought Notice - Alcon Wavecards
02/14 IMMUNICUM : Appoints Karin Hoogendoorn as Head of CMC
02/09 NOVARTIS : Patent Issued for Microscope-Less Wide Field-Of-View Surgical OCT Vis..
02/09 NOVARTIS : Patent Issued for Ocular Implant Delivery Systems and Methods (USPTO ..
02/09 NOVARTIS : Ampersand Capital Partners and 1315 Capital to Acquire Genoptix
02/08 NOVARTIS : Medical researchers using new tools to turn science fiction into scie..
02/06 New GlaxoSmithKline CEO prepares for R&D choices, potential deals
02/03 Microsoft, Coca-Cola, Novartis, L`Oral, Nokia and more Join Ethisphere`s Glob..
02/02 NOVARTIS : Patent Issued for Complement Pathway Modulators and Uses (USPTO 95507..
More news
Sector news : Pharmaceuticals - NEC
12:03pDJBAYER : CEO Confident Monsanto Purchase Will Be Approved by End of Year -- Updat..
10:03aDJBAYER : Upbeat Bayer Posts Lower Profit With Monsanto in its Sights--Update
08:48aDJBRISTOL MYERS SQUIBB : New Pressure on Drug Giant -- WSJ
08:48aDJWHAT'S NEWS : Business & Finance -- WSJ
08:02aDJBAYER : Fourth-Quarter Net Profit Falls 26%
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/21 HEPATITIS B MARKET : Emerging Players Could Make The Difference
02/21 Merck Provides Keytruda For Bionomics Phase 1 Trial On Combination With BNC10..
02/21 VBL's lead product candidate successful in mid-stage thyroid cancer study; sh..
02/21 This Biotech ETF Looks Primed To Rally Again
02/17 INCYTE : Many Strengths, Small EPS, So What's It Worth?
Advertisement
Financials ($)
Sales 2017 48 441 M
EBIT 2017 11 334 M
Net income 2017 7 521 M
Debt 2017 16 963 M
Yield 2017 3,70%
P/E ratio 2017 23,23
P/E ratio 2018 20,39
EV / Sales 2017 4,54x
EV / Sales 2018 4,29x
Capitalization 202 892 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 80,4 $
Spread / Average Target 4,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG3.51%202 892
JOHNSON & JOHNSON3.86%325 539
ROCHE HOLDING LTD.4.90%212 000
PFIZER INC.3.51%204 018
MERCK & CO., INC.11.23%180 537
SANOFI4.72%109 519
More Results